DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Post ERCP Pancreatitis Prevention in Average Risk Patients

Information source: University Hospital Rijeka
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Pancreatitis

Intervention: Ceftazidime (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University Hospital Rijeka

Official(s) and/or principal investigator(s):
Goran Hauser, MD, PhD, Principal Investigator, Affiliation: University Hospital Rijeka

Summary

Diclophenac potassium and ceftazidime are commercially available drugs that are used in various clinical situations. They are safe and known for years. Diclophenac potassium and Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is currently standard treatment for prevention of (PEP) while ceftazidime is possible alternative treatment for patients with contraindications for nonsteroidal medicines. The aim of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.

Clinical Details

Official title: Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention

Primary outcome: Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium

Detailed description: Study type: Interventional Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: only Investigator Primary Purpose: Prevention Study Phase: Phase 4 Conditions or Focus of the study: Post ERCP pancreatitis Intervention information

- Intervention Names ERCP

- Arm Information

- Arm 1: Ceftazidime

- Arm 2 (active comparator): Diclophenac potassium

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- o All patients undergone to ERCP irrespectively about the diagnosis

Exclusion Criteria:

- o Unwillingness or inability to consent for the study

- Age < 18 years

- Previous ERCP (papillotomy)

- Intrauterine pregnancy

- Breast feeding mother

- Allergy to Aspirin or NSAIDs and Ceftazidime

- NSAID or antibiotic use within 1 week (ASA 325 mg daily or less acceptable)

- Renal failure (Cr > 1. 4)

- Active or recent (within 4 weeks) gastrointestinal hemorrhage

- Existing acute pancreatitis (lipase peak) within 72 hours prior to ERCP

- Anticipated inability to follow protocol

Locations and Contacts

Clinical Hospital Centre, Rijeka, Kresimirova 42 51000, Croatia
Additional Information

Starting date: June 2013
Last updated: April 6, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017